

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



2 May 2023

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SUNPHARMA

Stock Code: 524715

Dear Sirs,

Sub: Deuruxolitinib (CTP-543) Clinical Program Update

Following a recent submission to the US FDA, we had a teleconference call with the agency, regarding a pulmonary embolism (Serious Adverse Events) occurring at the 12 mg BID dose in one of the long-term Open Label Extension (OLE) studies. As a result, the agency has placed the IND on partial clinical hold, due to the potential for thrombotic events, and are requiring that subjects currently on the 12 mg BID dose in the OLE studies to discontinue that dose. There have been no thrombotic events reported to date for the 8 mg BID dose and US FDA has not placed the 8 mg BID dose on hold. We are taking immediate steps to transition the patients in the OLE studies to the 8 mg BID dose arm in the ongoing studies.

No thromboembolic events were observed during Phase-2 or Phase-3 trials, and we remain confident in deuruxolitinib's potential to treat patients with Alopecia Areata and will work closely with the US FDA to address the agency's concerns. US FDA is expected to state the concerns in a formal letter, expected within the next 30 days.

Deuruxolitinib is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2 being studied for the treatment of Alopecia Areata. In addition to Breakthrough Therapy designation for the treatment of adult patients with moderate to severe Alopecia Areata, the US FDA has also granted deuruxolitinib Fast Track designation for the treatment of Alopecia Areata.

This is for your information and dissemination.

Thanking you,

Yours faithfully,
For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary & Compliance Officer

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.